Near-Perfect Disease Control for Bispecific in Advanced Endometrial Cancer

(MedPage Today) -- SAN JUAN, Puerto Rico -- Almost 100% of patients with recurrent/metastatic endometrial cancer benefited from an investigational bispecific antibody plus standard chemotherapy, according to a small preliminary study from China...
Source
MedPage Today
Opens original article in a new tab



